Pipeline
A Fully Integrated Pipeline From Target To Molecule To Clinical Development
Coupling our target discovery platforms ATLAS and SUMMIT with our unique drug discovery and development capabilities, we are advancing medicines for high unmet need areas with a focus on oncology.
Our most advanced programs consist of tailored T-cell engagers optimized for each target and designed to maximize safety and anti-tumor activity, with discovery programs including T-cell engagers and other antibody formats.
| Program | Target Category | Phase |
|---|---|---|
|
Program
CBI-1214MSS/MSI-L Colorectal Cancer |
Target Category
Novel |
Phase
Phase 1 |
|
Bispecific T cell engager. CBI-1214 has been engineered to maximize anti-tumor activity across the MSS/MSI-L colorectal cancer population. Clinical Trial: https://clinicaltrials.gov/search?term=cbi-1214 |
||
|
Program
CB02Multiple Malignancies |
Target Category
Novel |
Phase
Pre-clinical |
|
Bispecific T cell engager targeting an undisclosed tumor cell surface protein that is broadly expressed in various hematological malignancies and solid tumors. |
||
|
Program
Pancreatic Cancer |
Target Category
Logic-gated |
Phase
Discovery |
|
Program
Hepatocellular Cancer |
Target Category
Single and logic-gated |
Phase
Discovery |
|
Program
Prostate Cancer |
Target Category
Single and logic-gated |
Phase
Discovery |
|
Program
Renal Cell Cancer |
Target Category
Single and logic-gated |
Phase
Discovery |
Partnerships
Delivering Innovation and Value to your Pipeline
Large and small biopharma organizations are benefiting from our platform and expertise, resulting in new, expanded, rejuvenated and optimized clinical assets.
 |
Announced in May 2024, Cartography and Gilead are collaborating to discover and develop precision oncology therapies for triple-negative breast cancer and lung adenocarcinoma. In April 2026, Gilead exercised its first target option for a novel oncology target discovered and validated through the collaboration. |
|---|---|
 |
Announced in January 2026, Cartography and Pfizer are collaborating to identify tumor-selective antigens for next-generation precision cancer therapies. |
Access & Compassionate Use Policy
Cartography Biosciences is building a differentiated oncology pipeline of antibody-based therapies designed to target tumors more precisely than existing therapeutics. We are committed to developing our medicines through rigorous clinical research in areas of unmet need. Currently, we do not offer expanded access to our investigational therapies outside of clinical trials. We believe that participation in clinical trials is the most appropriate and equitable pathway for patients until the safety and tolerability of an investigational therapy has been established and evaluated by regulatory authorities. We will update this policy if the status changes.
For more information about our ongoing studies, please visit clinicaltrials.gov and search “Cartography Biosciences” to find our clinical trials that may be recruiting. If you are a healthcare professional and would like more information on our investigational therapies please send an inquiry to clinicaltrials@cartography.bio. Information about FDA’s expanded access program is available through their website.
Partner With Us
Building the Best Pipeline Together
We believe collaborations create tremendous value for patients. Our platform and expertise ensures that clinical pipelines are built around the best targets.
